GT Biopharma Reports Second Quarter 2026 Financial Results
Globe Newswire•14/08/2026•08:00 ET
0
Whiz Insights
Phase 1 trial evaluating GTB-3650 TriKE(®) remains ongoing, with an update anticipated in 2H 2026
Phase 1 basket trial evaluating GTB-5550 TriKE(® )in multiple solid tumor types known to express B7-H3 initiated May 2026 with an update anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts
Get started
Create a free account to read the full story.